Literature DB >> 9787684

Randomized controlled trial of ipratropium bromide and frequent low doses of salbutamol in the management of mild and moderate acute pediatric asthma.

F M Ducharme1, G M Davis.   

Abstract

OBJECTIVES: To compare the effectiveness and safety of alternative nebulized drug protocols in children with mild or moderate asthma exacerbations.
METHODS: We conducted a blinded, randomized, controlled trial with a 2 x 2 factorial design. Two interventions, nebulized salbutamol in frequent low doses (0.075 mg/kg every 30 minutes) and the addition of ipratropium bromide (250 micrograms), were compared with salbutamol in hourly high doses (0.15 mg/kg every 60 minutes) in children with mild or moderate acute asthma. The primary end point was the improvement in respiratory resistance. Secondary end points included oxygen saturation, corticosteroid use, patient disposition, and relapse status.
RESULTS: A total of 298 participants aged 3 to 17 years were studied, and 15% were admitted to the hospital; 14% of the children had relapses. No increased bronchodilation was associated with frequent low doses versus hourly high doses of salbutamol (RR = 0.9 [95% confidence interval 0.7, 1.3]) or the addition of ipratropium bromide versus placebo (RR = 1.0 [0.8, 1.3]). No group differences were observed in secondary end points. Salbutamol in frequent low doses was associated with increased vomiting (RR = 2.5 [1.1, 6.0]).
CONCLUSION: Our results do not support the use of frequent low doses of nebulized salbutamol or the addition of ipratropium bromide compared with hourly high doses of salbutamol in children with mild or moderate asthma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9787684     DOI: 10.1016/s0022-3476(98)70054-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  10 in total

Review 1.  Management of acute pediatric asthma.

Authors:  John C Carl; Carolyn M Kercsmar
Journal:  Curr Allergy Asthma Rep       Date:  2002-11       Impact factor: 4.806

Review 2.  Management of children with severe asthma exacerbation in the emergency department.

Authors:  Benjamin Volovitz; Moshe Nussinovitch
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 3.  Antiasthmatic drug delivery in children.

Authors:  Elizabeth Biggart; Andrew Bush
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

Review 4.  Canadian Asthma Consensus Report, 1999. Canadian Asthma Consensus Group.

Authors:  L P Boulet; A Becker; D Bérubé; R Beveridge; P Ernst
Journal:  CMAJ       Date:  1999-11-30       Impact factor: 8.262

Review 5.  Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis.

Authors:  G J Rodrigo; J A Castro-Rodriguez
Journal:  Thorax       Date:  2005-07-29       Impact factor: 9.139

6.  Nebulized salbutamol vs salbutamol and ipratropium combination in asthma.

Authors:  Anita Sharma; Arvind Madaan
Journal:  Indian J Pediatr       Date:  2004-02       Impact factor: 1.967

Review 7.  Should inhaled anticholinergics be added to beta2 agonists for treating acute childhood and adolescent asthma? A systematic review.

Authors:  L H Plotnick; F M Ducharme
Journal:  BMJ       Date:  1998-10-10

8.  Determinants Of Oral corticosteroid Responsiveness in Wheezing Asthmatic Youth (DOORWAY): protocol for a prospective multicentre cohort study of children with acute moderate-to-severe asthma exacerbations.

Authors:  F M Ducharme; R Zemek; J Gravel; D Chalut; N Poonai; S Laberge; C Quach; M Krajinovic; C Guimont; C Lemière; M C Guertin
Journal:  BMJ Open       Date:  2014-04-07       Impact factor: 2.692

Review 9.  Anticholinergic therapy for chronic asthma in children over two years of age.

Authors:  N J McDonald; A I Bara
Journal:  Cochrane Database Syst Rev       Date:  2003

10.  Combination of ipratropium bromide and salbutamol in children and adolescents with asthma: A meta-analysis.

Authors:  Hongzhen Xu; Lin Tong; Peng Gao; Yan Hu; Huijuan Wang; Zhimin Chen; Luo Fang
Journal:  PLoS One       Date:  2021-02-23       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.